PNU-142731A Pharmacia.
Pharmacia is developing PNU-142731A, a potential lead compound as a treatment for asthma [294718]. It is in phase I clinical trials. PNU-142731A is a potent inhibitor of eosinophilic lung inflammation in rodents, and shows a good bioavailability profile in animals; the mechanism of action is being investigated. Unlike the original compound PNU-104067F, PNU-142731A does not give rise to gall bladder toxicity [295987], [298023].
University of Southampton School of Medicine, Division of Respiratory Cell & Molecular Biology, Centre Block-Level D, Tremona Road, Southampton, SO16 6YD, UK. Gordon_Dent@compuserve.com
G
G
Dent
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000138:chemical synthesis / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D001249:Asthma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000138:chemical synthesis / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D007211:Indoles / Q000138:chemical synthesis / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D011759:Pyrrolidines / Q000138:chemical synthesis / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D013329:Structure-Activity Relationship
D018927:Anti-Asthmatic Agents; D015507:Drugs, Investigational; D007211:Indoles; C120149:PNU 142731A; D011759:Pyrrolidines